Clinical Trials Logo
  1. Home
  2. Metastatic Renal Cancer
  3. NCT02837757

Everolimus Modulation of Anti-tumor T CD4 Immune Responses — EMIR  

Metastatic Renal Cancer Clinical Trial

Official title:
Everolimus Modulation of Anti-tumor T CD4 Immune Responses

Clinical Trial Summary

Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02837757
Study type Interventional
Source Centre Hospitalier Universitaire de Besancon
Contact
Status Terminated
Phase N/A
Start date November 2015
Completion date December 18, 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02479490 - PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI Phase 2
Terminated NCT01457131 - Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer Phase 1
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Recruiting NCT03630692 - Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
Terminated NCT01160445 - Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer Phase 2
Recruiting NCT04316520 - Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma N/A
Terminated NCT01273181 - MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes Phase 1/Phase 2
Completed NCT02086734 - Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma